Is a
Acquisition attributes
Acquired Company
Acquirer
Date Announced
January 3, 2019
ATAI Life Sciences acquired a majority stake in Perception Neuroscience alongside a consortium of private equity and venture capital firms.
Participating investors included private equity firm Morgan Noble Healthcare Partners, venture capital firm Subversive Capital LLC, and life sciences investor WPSS Investments.
Perception founders Jonathan Sporn and Jay Kranzler will retain minority stakes in the company, which is developing a ketamine-based rapid-acting antidepressant drug.
PJT Partners advised on the transaction.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
